youtube_live
Q2 2027 earnings • 5:30 AM tomorrow
See detailschevron_right
IPCALAB:NSE
IPCA Laboratories Ltd
₹1,972.50
arrow_upward
+1.15%(+22.40) 1D
Nov 4, 3:30:02 PM GMT+5:30 · INR
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IPCALAB...
Open
₹1,955.00
High
₹1,995.00
Low
₹1,955.00
Mkt. cap
500.43B
Avg. vol.
240.55K
Volume
402.86K
Dividend
0.30%
Quarterly dividend
₹1.50
Ex-dividend date
Aug 7, 2026
P/E ratio
38.21
52-wk high
₹2,038.00
52-wk low
₹1,276.10
EPS
₹51.63
Shares outstanding
126.35M
No. of employees
17K
Open
₹1,955.00
High
₹1,995.00
Low
₹1,955.00
Mkt. cap
500.43B
Avg. vol.
240.55K
Volume
402.86K
Dividend
0.30%
Quarterly dividend
₹1.50
Ex-dividend date
Aug 7, 2026
P/E ratio
38.21
52-wk high
₹2,038.00
52-wk low
₹1,276.10
EPS
₹51.63
Shares outstanding
126.35M
No. of employees
17K
News stories
From web sources and news partners
Virginia Business
·
32 minutes ago
Accendra Health could be delisted by NYSE
Yahoo Finance
·
16 minutes ago
The Nasdaq-100 Is Outperforming Nvidia, Microsoft, Amazon, Meta Platforms, Alphabet, and Tesla This Year. Here's My Favorite Low-Cost ETF to Buy the Dip.
The Washington Post
·
2 hours ago
The S&P 500 climbs after Democrats sweep the midterms
The Motley Fool
·
1 hour ago
If the S&P 500 Falls 20%, Here's the 1 ETF I'd Buy Hand Over Fist
Profile
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients, covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries.
Ipca is one of the largest global suppliers of the antimalarials hydroxychloroquine and chloroquine, as well as of APIs such as atenolol, chlorthalidone, losartan and metoprolol. Since 2023, it has held a majority stake in Unichem Laboratories. The company is listed on the BSE and the National Stock Exchange of India, and reported consolidated revenue of ₹9,646 crore in the financial year ended 31 March 2026. Wikipedia
About IPCA Laboratories Ltd
CEO-
Employees17.2K
FoundedOct 19, 1949
Headquarters-
SectorPharmaceutical industry
Industry-
Websiteipca.com
Next call in 13:08:59
Tomorrow, 5:30 AM
Fiscal period
Q2 2027
- Normalized EPS / Est. (INR)
- GAAP EPS / Est. (INR)
- / ₹16.20
Revenue / Est. (INR)
- / 28.64B
Fiscal Q2 2027 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in INR | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 25.56B | 23.92B | 23.89B | 27.88B |
Cost of goods sold | 7.82B | 6.58B | 10.31B | 7.97B |
Cost of revenue | 7.82B | 6.58B | 10.31B | 7.97B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 5.38B | 5.46B | 5.54B | 6.02B |
Operating expense | 13.33B | 13.09B | 9.17B | 14.32B |
Total operating expenses | 21.15B | 19.67B | 19.48B | 22.29B |
Operating income | 4.42B | 4.26B | 4.41B | 5.59B |
Other non operating income | 278.60M | 201.90M | -680.30M | 252.60M |
EBT including unusual items | 3.89B | 4.46B | 4.02B | 5.74B |
EBT excluding unusual items | 4.47B | 4.28B | 3.62B | 5.74B |
Income tax expense | 1.08B | 819.30M | 950.50M | 1.49B |
Effective tax rate | 27.81% | 18.39% | 23.66% | 26.03% |
Other operating expenses | 6.92B | 6.55B | 2.56B | 7.20B |
Net income | 2.83B | 3.26B | 2.99B | 4.02B |
Net profit margin | 11.05% | 13.64% | 12.52% | 14.41% |
Earnings per share | 12.35 | 12.09 | 13.31 | 15.84 |
Interest and investment income | - | - | 317.20M | - |
Interest expense | -196.10M | -176.20M | -199.90M | -118.80M |
Net interest expenses | -196.10M | -176.20M | 117.30M | -118.80M |
Depreciation and amortization charges | 1.03B | 1.08B | 1.04B | 1.11B |
EBITDA | 5.43B | 5.18B | 5.37B | 6.55B |
Gain or loss from assets sale | - | - | - | - |
Upcoming events